{"nctId":"NCT00450112","briefTitle":"Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee","startDateStruct":{"date":"2007-03"},"conditions":["Osteoarthritis of the Knee"],"count":202,"armGroups":[],"interventions":[{"name":"Gel-200","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previous participation in study SI-6606/01.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Occurrence of Systemic and Local Adverse Events Following a Single or Repeat Intra-articular Injection of Gel-200","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS) (Pain Subscore)","description":"Observed WOMAC pain subscore on VAS of 100 mm.; 0 mm meaning no pain; 100 mm meaning extreme pain. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"22.68"},{"groupId":"OG001","value":"35.4","spread":"22.97"}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in WOMAC VAS (Stiffness Subscore)","description":"Observed WOMAC stiffness subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no stiffness; 100 mm meaning extreme stiffness. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"24.95"},{"groupId":"OG001","value":"34.5","spread":"25.27"}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in WOMAC VAS (Physical Function Subscore)","description":"Observed WOMAC physical function subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no difficulty; 100 mm meaning extreme difficulty. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"22.85"},{"groupId":"OG001","value":"34.4","spread":"24.04"}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in WOMAC VAS (Total Score)","description":"Observed all WOMAC mean scores on Visual Analog Scale (VAS) of 100 mm; a total of WOMAC pain, stiffness, and physical function subscores. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"22.60"},{"groupId":"OG001","value":"34.6","spread":"23.66"}]}]}]},{"type":"SECONDARY","title":"Outcome Measures in Rheumatology Artthritis Clinical Trials (OMERACT) - and the Osteoarthritis Research Society International (OARSI) Response","description":"Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) strict responses defined by improvements from baseline in WOMAC pain or physical function subscore ≥50% with absolute changes ≥20 mm (termed strict responders), or ≥20% with absolute changes ≥10mm in 2 of 3 measures of WOMAC pain or physical function subscore or subject global evaluations (termed responders).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"77.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in Subject Global Evaluations","description":"Observed subject evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":"30.76"},{"groupId":"OG001","value":"33.4","spread":"26.24"}]}]}]},{"type":"SECONDARY","title":"Improvement From Baseline in Physician Global Evaluations","description":"Observed physician evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Improved score from baseline to week 13 were calculated as baseline minus week 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":"25.08"},{"groupId":"OG001","value":"27.4","spread":"27.15"}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Consumption","description":"Weekly mean acetaminophen consumption between weeks 9 and 13.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1677.4","spread":"3135.80"},{"groupId":"OG001","value":"1822.5","spread":"2768.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":125},"commonTop":["Joint effusion","Joint swelling","Arthralgia"]}}}